Sat, Feb 28, 2015, 6:59 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Exelixis, Inc. Message Board

  • biglabowski99 biglabowski99 Mar 6, 2013 6:22 PM Flag

    Multimodality imaging investigation of response to cabozantinib in a VCaP model of prostate bone metastasis

    i might start charging : )

    Prostate cancer (PCa) growth is incurable once it has metastasized to the bone microenvironment (BM). The altered BM provides a permissive niche to support tumour growth, and therapeutic strategies that target tumour-bone interactions and/or restore bone homeostasis are being pursued. This demands preclinical models that faithfully replicate tumour-bone interactions, and non-invasive imaging methods to interrogate such orthotopic models in vivo, improving the accuracy of, and accelerating pre-clinical drug development. We have used a multi-modality imaging approach to assess the radiology and response of an orthotopic VCaP PCa bone metastasis model to the c-Met/VEGFR2 inhibitor cabozantinib.
    Direct intratibial injection of 2x106 luc-VCaP cells into male castrate SCID mice resulted in tumour formation within 20 days. The resulting tumours deregulated normal bone function, exhibited a predominantly sclerotic phenotype and, importantly, retained a rearrangement of the ERG oncogene, the most common chromosomal abnormality found in human PCa (40-80% of cases). Mice bearing established intratibial VCaP prostate tumours were treated daily with 30mg/kg p.o. cabozantinib (n=7) or vehicle alone (n=7) for 15 days.
    Semi-quantitative photon flux measures from BLI showed a 52% regression after 14 days of treatment (p=0.016). Tumour volume was quantified from T2-weighted MR images acquired from contiguous transverse 500μm slices across the leg, with an in-plane resolution of 156μm2, in which tumour hyperintensity was clearly identifiable. Mean tumour volume was significantly (p=0.038) smaller in the cabozantinib treated group after 15 days treatment (21.9 ± 5.1 mm3) compared to the vehicle cohort (104 ± 43 mm3). These data show that cabozantinib exhibits powerful anti-tumour activity in this clinically relevant model of PCa.
    Diffusion weighted MR images were acquired using a 10 b-value EPI sequence, from which the apparent diffusion coefficient (ADC),

 
EXEL
2.930.000(0.00%)Feb 27 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.